



# Medicapital, Inc.

\*Disclaimer- All the documents in the blog were created as part of a series of projects for a technical writing course in college. All information provided within the documents are falsified and intended for classroom use.

Date: April 8th, 2017  
To: Brett J. Millán, CEO of Medicapital Inc.  
From: Haley Smith, Researcher  
Subject: Report on Researching Companies for Investment

## ***Purpose***

The goal of this report is to present evaluated information on which of the following cancer treatment research companies would be the best candidate for investment.

## ***Summary***

Five companies were selected for a study in their prospective success in research of cancer treatments. The companies that were chosen to be observed in this study were Applera Corp-Celera, Onyx Pharmaceuticals, United Therapeutics, Crucell NV, and Mannkind Corp. The topics of study included the company's time in business, the 52-week highs and lows of each company's respective stock, clinical trials conducted, and partnerships formed with other companies. This research shows that Onyx Pharmaceuticals and United Therapeutics best represent and reflect the goals of Medicapital, Inc.

## ***Results of Research***

### **Applera Corp-Celera**

Now known as the Celera Corporation, this company was founded in 1998 as a business unit of the biotechnology company Applera. Celera became an independent company in 2008, and in 2011 it was acquired by Quest Diagnostics. Celera Corp mainly focuses on the development, manufacturing, marketing, and distribution of molecular diagnostic products, such as antiretroviral drugs and genotyping systems that detect genomic mutations.

**Partners:** Applied Biosystems, Montefiore Health System, Optum, Safeway, Hartford Healthcare

### **Drugs in clinical trials:**

HBV drug therapy to treat hepatitis B.

ViroSeq HCV - vaccine for hepatitis C.

Viroseq, HIV Integrase

**NASDAQ: CRA**

**52 Week high:** \$100

**52 Week low:** \$72.39

### **Onyx Pharmaceuticals**

Onyx pharmaceuticals is a biopharmaceutical company that was founded in 1992. In 2009, the company was acquired by Proteolix, Inc., a private organization with a specialization in biotechnological advancement. Onyx Pharmaceuticals was acquired by Amgen in 2013. Onyx under Amgen specializes on the development of commercial therapies for cancer treatments. Onyx Pharmaceuticals has released treatments that have been approved in the U.S. and have been successfully put through clinical trials.

**Partners:** Ono pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc., AstraZeneca, UCB SA, Carmot Therapeutics, Regeneron Pharmaceuticals, Watson Pharmaceuticals

**Drugs in clinical trials: (3 cancer related treatments)**

Nexavar (Sorafenib) - approved in the U.S for the treatment of renal cell carcinoma.

The drug was also tested in trials for alternative forms of cancer, including breast and thyroid cancers.

Kyprolis (Carfilzomib) - approved by the FDA 2012 and is used in treatment for patients with multiple myeloma.

Stivarga (Regorafenib) - under current study and trial for treating tumors of multiple types. In 2012 however, the FDA approved the drug for the use of treating metastatic colorectal cancer (CRC).

**NASDAQ: CRA**

**52 week high:** \$184.21

**52 week low:** \$133.64

**United Therapeutics**

United Therapeutics is a company that was founded in 1996 as Lung Rx, Inc. It focuses on the development and commercialization of biotechnology and treatments for patients with chronic and life-threatening conditions. United Therapeutics has successfully provided 5 drugs that were approved by the FDA.

**Partners:** Children's Oncology Group, Respira Therapeutics

**Drugs in clinical trials: (5 hyper-tension centered drugs, 1 cancer related)**

Adcirca (PDE-5) - effective drug approved for usage in the U.S for the treatment of pulmonary arterial hypertension

Orenitram - treatment of pulmonary hypertension.

Remodulin - treatment of pulmonary arterial hypertension.

Tyvaso - treatment of pulmonary arterial hypertension.

Unituxin - treatment of high-risk neuroblastoma.

**NASDAQ: CRA**

**52 week high:** \$169.8899

**52 week low:** \$97.52

**Crucell NV**

Crucell NV was founded in 1993. The company joined Janssen Pharmaceutical Corp. of Johnson & Johnson in 2011. The pharmaceutical company focuses on the research and development of treatment for antibodies and infectious diseases. They have developed effective vaccines against hepatitis B, influenza, typhoid, cholera and hepatitis A.

**Partners:** DSM biologics, Sanofi-Aventis, Novartis, Wyeth, GSK, CSL and Merck & Co.

**Drugs in clinical trials:** (7 vaccines)

Quinvaxem

Hepavax-Gene, Epaxal - vaccinations and treatments for hepatitis.

MoRu-Viraten - vaccine for measles.

Vivotif - vaccine for typhoid.

Dukoral - vaccine for cholera.

Inflexal - vaccine for influenza.

**NASDAQ: CRA**

**52 week high:** \$129

**52 week low:** \$108.75

### **Mannkind Corp**

Mannkind Corp was founded in 1991. Mannkind Corp is a biopharmaceutical company that is centered around the development and commercialization of therapeutic products for patients with insulin needs and diabetes.

**Partners:** JDRF, Sanofi, Receptor Life Sciences

**Drugs in clinical trials:** Afrezza (insulin) inhalation powder is their first FDA-approved product.

**NASDAQ: CRA**

**52 week high:** \$10.15

**52 week low:** \$1.16

### ***Conclusion***

Onyx Pharmaceuticals and United Therapeutics are companies that reflect Medicapital's investment goals and requirements. Both companies display a commitment to the development and commercialization of treatment products that coincide with Medicapital's interests. The companies have FDA approved clinical drugs related to the advancement and treatment of cancer, making them an important asset in investment towards Medicapital's goals of cancer treatment progress and innovation.